“Hematologic malignant tumors are among the most prevalent cancers in the United States,” Daniel Clayburgh, MD, PhD, and colleagues wrote. “This large population of patients is unfortunately susceptible to future cancers. Studies of hematologic malignant tumors, such as chronic myelogenous leukemia, chronic lymphocytic leukemia or small lymphocytic lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma, have demonstrated long-term elevated risk [for] developing secondary neoplasms. In studies of patients who have undergone hematopoietic stem cell transplant ... there is also a significantly elevated risk [for] second cancers.”

• Aerodigestive tract cancer (relative risk 16)
• Oral cavity cancer (relative risk 1.7)
• Oropharynx cancer (relative risk 1.7)
• Larynx cancer (relative risk 1.3)
• Sinonasal Cancer (relative risk 3)
• Salivary gland cancer (relative risk 2.8)
• Thyroid cancer (relative risk 2.1)